Weight

Every compound in the sci-wiki that affects weight; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

0 sourced · 3 reference

←weight3/3

Peptide

Eloralintide

Eloralintide is an injectable amylin-receptor agonist from Eli Lilly, in phase 3 for obesity. It is a modified 37-residue amylin analogue carrying a C20 fatty diacid that binds albumin and stretches its half-life to roughly two weeks, allowing weekly dosing with an unusually flat blood level [2]. What distinguishes it from the other amylin drugs is a deliberate attempt at receptor selectivity: it is about twelve-fold more potent at the amylin 1 receptor than at the calcitonin receptor in human cells [1]. In a 48-week phase 2 trial it produced up to 20 percent weight loss [3].

reference

Peptide

Petrelintide

Petrelintide is a long-acting amylin analogue from Zealand Pharma, in phase 2 for obesity and partnered with Roche. It is built on the human amylin backbone rather than the rat sequence pramlintide uses, with a lactam bridge replacing the native disulfide and a C20 diacid for albumin binding, giving a half-life of about ten days [1][2]. ⚠️ It is widely described as a selective amylin analogue, and its sponsor's own data show it is not: it is equally potent at the calcitonin receptor [1].

reference

Peptide

UBT-251

UBT-251 is an injectable peptide developed by United Bio-Technology in Hengqin and licensed to Novo Nordisk, described as a triple agonist at the GLP-1, GIP and glucagon receptors. ⚠️ It has no peer-reviewed literature of any kind. Eleven trials are registered, including three phase 3 studies, and not one journal publication exists; there is no published sequence, no structure, no receptor potency and no reported trial result. That combination is the most important thing to know about it.

reference